Thu, Dec 25, 2014, 1:11 PM EST - U.S. Markets closed for Christmas

Recent

% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

  • gladpick gladpick Nov 27, 2012 1:29 PM Flag

    GILDreport

    SVR12 was 80%. The only problem is that it was based on geno 2 and geno 3--the easier to treat group.
    Below is the government's defintion of the 3 HCV genotypes.

    Genotype 1 (more difficult to treat)
    Approximately 72% of Americans with hepatitis C have genotype 1
    Chance of clearing hepatitis C virus is 42-46%
    Treatment usually lasts for 1 year
    Ribavirin dosage usually is higher than that required to treat other genotypes

    Genotype 2 (easier to treat)
    Approximately 10% of Americans with hepatitis C have genotype 2
    Chance of clearing hepatitis C virus is 65-80%
    Treatment usually lasts for 6 months
    Ribavirin dosage usually is lower than that required to treat genotype 1

    Genotype 3 (easier to treat)
    Approximately 6% of Americans with hepatitis C have genotype 3
    Chance of clearing hepatitis C virus is 65-80%
    Treatment usually lasts for 6 months
    Ribavirin dosage usually is lower than that required to treat genotype 1

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
VRTX
115.15+1.40(+1.23%)Dec 24 1:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Yahoo! Inc.
NASDAQWed, Dec 24, 2014 1:00 PM EST
Noble Energy, Inc.
NYSEWed, Dec 24, 2014 2:48 PM EST